Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis

Leukemia Research

Volumn 36, Issue 8, 2012, Pages 1016-1021

  Kagoya, Yuki ^a   Nannya, Yasuhito ^a   Kurokawa, Mineo ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Corticosteroid; Maintenance therapy; Meta analysis; Multiple myeloma; Randomized controlled trials; Thalidomide

Indexed keywords

BORTEZOMIB; CORTICOSTEROID; INTERFERON; THALIDOMIDE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ASSESSMENT; DRUG EFFICACY; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; VEIN THROMBOSIS;

ADRENAL CORTEX HORMONES; AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 84862512787     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.04.001     Document Type: Article

References (34)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Child J.A., Morgan G.J., Davies F.E., Owen R.G., Bell S.E., Hawkins K., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
3. Kumar S.K., Rajkumar S.V., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
4. Brenner H., Gondos A., Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008, 111:2521-2526.
5. Belch A., Shelley W., Bergsagel D., Wilson K., Klimo P., White D., et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988, 57:94-99.
6. Berenson J.R., Crowley J.J., Grogan T.M., Zangmeister J., Briggs A.D., Mills G.M., et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002, 99:3163-3168.
7. Shustik C., Belch A., Robinson S., Rubin S., Dolan S., Kovacs M., et al. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: a National Cancer Institute of Canada Clinical Trials Group Study: MY.7. J Clin Oncol (ASCO Annual Meeting Abstracts). 2004, 145:6510a.
8. Fritz E., Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomized trials among 3948 patients. Ann Oncol 2000, 11:1427-1436.
9. Facon T., Mary J.Y., Hulin C., Benboubker L., Attal M., Pegourie B., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial. Lancet 2007, 370:1209-1218.
10. Barlogie B., Attal M., Crowley J., van Rhee F., Szymonifka J., Moreau P., et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University Of Arkansas for Medical Sciences. J Clin Oncol 2010, 28:1209-1214.
11. Ludwig H., Adam Z., Tóthová E., Hajek R., Labar B., Egyed M., et al. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica 2010, 95:1548-1554.
12. Blade J., Samson D., Reece D., Apperley J., Björkstrand B., Gahrton G., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998, 102:1115-1123.
13. Durie B.G., Harousseau J.L., Miguel J.S., Bladé J., Barlogie B., Anderson K., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
14. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
15. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
16. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
17. Attal M., Harousseau J.L., Leyvraz S., Doyen C., Hulin C., Benboubker L., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108:3289-3294.
18. Barlogie B., Tricot G., Anaissie E., Shaughnessy J., Rasmussen E., van Rhee F., et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006, 354:1021-1030.
19. Barlogie B., Pineda-Roman M., van Rhee F., Haessler J., Anaissie E., Hollmig K., et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008, 112:3115-3121.
20. Abdelkefi A., Ladeb S., Torjman L., Othman T.B., Lakhal A., Romdhane N.B., et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008, 111:1805-1810.
21. Palumbo A., Bringhen S., Rossi D., Cavalli M., Larocca A., Ria R., et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010, 28:4976-4984.
22. Mateos M.V., Oriol A., Martínez-López J., Gutiérrez N., Teruel A.I., de Paz R., et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010, 11:934-941.
23. Offidani M., Corvatta L., Polloni C., Piersantelli M.N., Gentili S., Galieni P., et al. Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. Br J Haematol 2009, 144:653-659.
24. Maiolino A., Hungria V., Oliveira-Duarte G., Oliveira L.C., Mercante D.R., Miranda E., et al. Thalidomide+dexamethasone as maintenance after single autologous stem cell transplantation improves progression-free survival (PFS) in advanced multiple myeloma. A prospective Brazilian randomized trial. Blood (ASH Annual Meeting Abstracts) 2008, 112:3703.
25. Spencer A., Prince H.M., Roberts A.W., Prosser I.W., Bradstock K.F., Coyle L., et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009, 27:1788-1793.
26. Morgan G.J., Gregory W.M., Davies F.E., Bell S.E., Szubert A.J., Brown J.M., et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC myeloma IX results and meta-analysis. Blood 2012, 119:7-15.
27. Stewart A.K., Trudel S., Bahlis N.J., White D.J., Sabry W., Belch A., et al. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): the NCIC CTG MY.10 trial. Blood (ASH Annual Meeting Abstracts) 2010, 116:39.
28. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F.E., Tai Y.T., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96:2943-2950.
29. Attal M., Cristini C., Marit G., Caillot D., Facon T., Hullin C., et al. Lenalidomide maintenance after transplantation for myeloma. J Clin Oncol (ASCO Annual Meeting Abstracts) 2010, 28:15.
30. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
31. Hicks L.K., Haynes A.E., Reece D.E., Walker I.R., Herst J.A., Meyer R.M., et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 2008, 34:442-452.
32. Fonseca R., Baarlogie B., Bataille R., Bastard C., Bergsagel P.L., Chesi M., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004, 64:1546-1558.
33. Cavo M., Zamagni E., Tosi P., Cellini C., Cangini D., Tacchetti P., et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004, 89:826-831.
34. Rajkumar S.V., Hayman S., Gertz M.A., Dispenzieri A., Lacy M.Q., Greipp P.R., et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002, 20:4319-4323.